Suzetrigine (Journavx) for Pain Management After Spine Surgery
Prospective Evaluation of Suzetrigine (Journavx) in Spine Surgery: Signal Characterization and Trial-Design Optimization Using Historical Controls
This prospective, single-center interventional study will evaluate the effect of suzetrigine (Journavx), a selective NaV1.8 inhibitor, on postoperative opioid requirements in patients undergoing spine surgery. Participants receiving suzetrigine as part of standard perioperative care will be compared with matched historical controls treated with standard multimodal analgesia. The study aims to characterize the magnitude and variability of opioid-sparing effects during the immediate postoperative period, with primary assessment focused on inpatient opioid consumption during the first 48 hours after surgery.
Secondary objectives include evaluation of postoperative pain scores, opioid-related adverse events, hospital length of stay, discharge disposition, post-discharge opioid prescribing patterns, and healthcare utilization. Findings from this study will provide real-world evidence regarding the potential role of suzetrigine in spine surgery and will inform the design and endpoint selection of a future multicenter randomized clinical trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Postoperative pain management following spine surgery remains a significant clinical challenge. Patients undergoing lumbar decompression, fusion, and other major spine procedures frequently experience substantial postoperative pain, require high doses of opioid analgesics, and are at increased risk for opioid-related adverse events, including postoperative nausea and vomiting, ileus, urinary retention, oversedation, respiratory depression, delirium, and delayed mobilization. Although multimodal analgesia strategies are widely implemented, the use of nonsteroidal anti-inflammatory drugs may be limited in fusion procedures because of concerns regarding bone healing, and regional anesthesia techniques are not universally applicable. Consequently, opioids remain a primary component of perioperative pain management in many spine surgery patients.
Suzetrigine (Journavx) is a first-in-class, selective NaV1.8 inhibitor that provides analgesia through peripheral inhibition of pain signaling without the central nervous system effects associated with opioids. Clinical studies in acute postoperative pain have demonstrated effective analgesia, reduced reliance on rescue medication, and a favorable safety profile. Given the high opioid requirements and substantial burden of opioid-related complications in spine surgery, this population represents an important setting in which to evaluate the potential opioid-sparing effects of suzetrigine.
This prospective, single-center study will evaluate postoperative outcomes among patients undergoing spine surgery who receive suzetrigine as part of perioperative pain management. Outcomes will be compared with matched historical controls treated with standard multimodal analgesia. The primary objective is to estimate the magnitude of opioid reduction during the first 48 hours after surgery. Secondary objectives include evaluation of inpatient and post-discharge opioid utilization, postoperative pain scores, opioid-related adverse events, hospital length of stay, discharge disposition, readmissions, and healthcare resource utilization.
In addition to assessing clinical outcomes, the study is intended to characterize variability in treatment response across patient and procedural subgroups and to identify the most informative efficacy, safety, clinical, and economic endpoints for future investigation. Findings from this study will generate real-world evidence regarding the use of suzetrigine in spine surgery and will inform the design, endpoint selection, and sample size considerations for a future multicenter randomized clinical trial.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Bryan Ladd, MD
- Phone Number: 614-688-9440
- Email: Bryan.Ladd@osumc.edu
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 to 80 years. Scheduled to undergo elective posterior-only lumbar fusion involving 1 to 3 spinal levels.
Anticipated postoperative inpatient admission. Eligible for the institutional Enhanced Surgical Recovery (ESR) spine surgery pathway.
Able and willing to provide informed consent.
Exclusion Criteria:
- Known contraindication or hypersensitivity to suzetrigine. Chronic or daily opioid use prior to surgery. Clinically significant hepatic or renal dysfunction. Inability or unwillingness to comply with study procedures or follow-up assessments.
Prisoner at the time of surgery or hospitalization. Known pregnancy at the time of surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Suzetrigine Plus Standard Multimodal Analgesia
Participants undergoing elective posterior lumbar fusion surgery will receive suzetrigine (Journavx) in addition to standard multimodal analgesia. Suzetrigine will be administered as a 100 mg oral loading dose within 2 hours prior to surgery, followed by 50 mg orally every 12 hours for 14 days. Participants will also receive standard perioperative pain management according to the institutional Enhanced Surgical Recovery (ESR) spine surgery pathway, including acetaminophen, muscle relaxants, and opioid analgesics as clinically indicated. Outcomes will be compared with matched historical controls receiving standard multimodal analgesia without suzetrigine. |
Suzetrigine administered as a 100 mg oral loading dose preoperatively followed by 50 mg orally every 12 hours for 14 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Opioid Consumption During the First 48 Hours After Surgery
Time Frame: 48 hours postoperatively
|
Total inpatient opioid consumption, expressed as morphine milligram equivalents (MME), during the first 48 hours following surgery. Opioid use among participants receiving suzetrigine will be compared with matched historical controls receiving standard multimodal analgesia. |
48 hours postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily Total Opioid Consumption
Time Frame: Postoperative Days 1-7 (up to hospital discharge)
|
Daily opioid consumption, expressed as MME, during hospitalization. |
Postoperative Days 1-7 (up to hospital discharge)
|
|
Daily Intravenous Opioid Consumption
Time Frame: Postoperative Days 1-7 (up to hospital discharge)
|
Daily intravenous opioid use, expressed as MME, during hospitalization. |
Postoperative Days 1-7 (up to hospital discharge)
|
|
Postoperative Pain Burden
Time Frame: 24 and 48 hours postoperatively
|
Time-weighted area under the curve (AUC) of postoperative pain intensity based on routinely collected pain scores. |
24 and 48 hours postoperatively
|
|
Time to First Opioid Rescue Medication
Time Frame: Up to hospital discharge (average 3-7 days)
|
Time from initial suzetrigine administration to first rescue opioid administration |
Up to hospital discharge (average 3-7 days)
|
|
Incidence of Opioid-Related Adverse Events
Time Frame: Day 14 (±7 days) after surgery
|
Occurrence of opioid-related adverse events including nausea and vomiting, constipation, urinary retention, respiratory depression, sedation, delirium, and pruritus |
Day 14 (±7 days) after surgery
|
|
Time to First Ambulation
Time Frame: At first ambulation, up to hospital discharge (average 3-7 days)
|
Time from surgery to first ambulation of at least three steps with an assistive device. |
At first ambulation, up to hospital discharge (average 3-7 days)
|
|
Discharge Opioid Utilization
Time Frame: Day 14 (±7 days) after surgery
|
Total opioid consumption and opioid prescribing during the 14-day postoperative treatment period. |
Day 14 (±7 days) after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bryan Ladd, MD, Ohio State University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY20261199
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.